"Digoxin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666)
| Descriptor ID |
D004077
|
| MeSH Number(s) |
D04.210.500.155.580.130.500.436 D04.210.500.155.580.130.688 D09.408.180.261.436
|
| Concept/Terms |
Digoxine Nativelle- Digoxine Nativelle
- Nativelle, Digoxine
- Hemigoxine Nativelle
- Nativelle, Hemigoxine
Lanoxin- Lanoxin
- Lanoxin-PG
- Lanoxin PG
- Lenoxin
|
Below are MeSH descriptors whose meaning is more general than "Digoxin".
Below are MeSH descriptors whose meaning is more specific than "Digoxin".
This graph shows the total number of publications written about "Digoxin" by people in this website by year, and whether "Digoxin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2010 | 1 | 1 | 2 |
| 2011 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 2 | 1 | 3 |
| 2015 | 1 | 1 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2021 | 0 | 2 | 2 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Digoxin" by people in Profiles.
-
Systems biology-based drug repositioning identifies digoxin as a potential therapy for groups 3 and 4 medulloblastoma. Sci Transl Med. 2018 10 24; 10(464).
-
A general strategy to construct small molecule biosensors in eukaryotes. Elife. 2015 Dec 29; 4.
-
Serum digoxin concentrations and clinical signs and symptoms of digoxin toxicity in the paediatric population. Cardiol Young. 2016 Mar; 26(3):493-8.
-
Efficacy of digoxin in comparison with propranolol for treatment of infant supraventricular tachycardia: analysis of a large, national database. Cardiol Young. 2015 Aug; 25(6):1080-5.
-
Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF study. J Am Coll Cardiol. 2014 Aug 19; 64(7):660-8.
-
Bufalin is a potent small-molecule inhibitor of the steroid receptor coactivators SRC-3 and SRC-1. Cancer Res. 2014 Mar 01; 74(5):1506-1517.
-
Possible digoxin toxicity associated with concomitant ciprofloxacin therapy. Int J Clin Pharm. 2013 Oct; 35(5):673-6.
-
The study of antiarrhythmic medications in infancy (SAMIS): a multicenter, randomized controlled trial comparing the efficacy and safety of digoxin versus propranolol for prophylaxis of supraventricular tachycardia in infants. Circ Arrhythm Electrophysiol. 2012 Oct; 5(5):984-91.
-
Sodium ion channel mutations in glioblastoma patients correlate with shorter survival. Mol Cancer. 2011 Feb 11; 10:17.
-
Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation. Clin Pharmacokinet. 2010 Apr; 49(4):223-37.